Abstract
ID 14907 Poster Board 257 Background: Eugenol is a simple and widely available hydrocarbon derivative primarily found in cloves, as well as other natural sources like cinnamon and nutmeg. Its phenolic structure suggests that eugenol has the ability to exhibit antioxidant activity. The literature also suggests that eugenol may possess anti-inflammatory properties. The goal of this project was to investigate whether eugenol was capable of protecting against diclofenac-induced hepatocellular injury. Diclofenac, a non-steroidal anti-inflammatory drug (NSAID) has been reported to elevate serum aminotransferase levels, and in some cases may cause serious liver injury. Methods: The toxicity of eugenol and diclofenac were measured by determining a median lethal dose (LC50) in an in vitro mouse liver model (TAMH; transforming growth factor-α transgenic mouse hepatocytes). LC50 values were determined using probit regression analysis in the SPss statistical tool package. TAMH cells were then exposed to a low (non-toxic) dose of eugenol (0.05 mg/mL) for varying pretreatment times before being exposed to a toxic dose of diclofenac (0.70 mg/mL) over a 24-hour period. Cell viabilities were measured following each eugenol/diclofenac treatment condition using a resazurin-based assay. Results: The LC50 values for eugenol and diclofenac were experimentally determined to be 0.14 and 0.57 mg/mL, respectively. An increase in cell viability (cytoprotective effect against diclofenac-induced toxicity) was directly correlated to eugenol pretreatment time. In fact, a five-day eugenol pretreatment resulted in an approximate 3-fold increase in the LC50 of diclofenac alone Conclusions: Relatively long-term eugenol exposure displayed hepatoprotective properties against diclofenac-induced injury. These findings suggest that eugenol may have utility as a dietary supplement capable of protecting the liver against toxic insult. In addition, eugenol might even improve therapeutic outcomes while simultaneously lowering the toxicity risk if combined with diclofenac. Future work is underway to not only explore mechanisms associated with eugenol’s cytoprotective ability against diclofenac-induced toxicity, but also to investigate a potentially synergistic relationship between eugenol and diclofenac related to cyclooxygenase (COX) inhibition. Funding Information: This work was supported by the Pacific University Research Incentive Grant Program and an ASPET Summer Undergraduate Research Fellow (SURF) Institutional Award.
Keywords